Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

NCT03106779 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

233

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG: Asciminib
DRUG: Bosutinib

Sponsor

Novartis Pharmaceuticals